Sign In
Buy UTHR
$549.47
+9.42 (+1.74%)
At Close: Jun 03, 2026
Traders Purchase Large Volume of United Therapeutics Call Options (NASDAQ:UTHR)
03:24am, Tuesday, 31'st Mar 2026
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) was the target of some unusual options trading on Monday. Investors bought 16,791 call options on the stock. This is an increase of app
United Therapeutics Stock Soars on Strong Phase 3 Lung Disease Results
01:21pm, Monday, 30'th Mar 2026
United Therapeutics (UTHR) surged 14% on Monday after the company reported positive Phase 3 results for nebulized Tyvaso in treating idiopathic pulmonary fibros
United Therapeutics shares surge after positive IPF trial results
11:41am, Monday, 30'th Mar 2026
Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of positive topline results from the Phase 3 TETON‑1 trial of its inhaled th
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 27'th Mar 2026
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
NorthCrest Asset Manangement LLC Purchases 1,843 Shares of United Therapeutics Corporation $UTHR
06:17am, Monday, 23'rd Mar 2026
NorthCrest Asset Manangement LLC grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 32.4% in the undefined quarter, according to its most recent filing with the SEC. The firm owned
Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience
02:55pm, Friday, 20'th Mar 2026
Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,072,050.00 in Stock
04:26am, Friday, 20'th Mar 2026
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
04:26am, Friday, 20'th Mar 2026
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction on Friday, March 13th. The stock was sold at an average
CPRX vs. UTHR: Which Stock Is the Better Value Option?
12:42pm, Wednesday, 18'th Mar 2026
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two companies is the bes
What Moved Markets This Week
06:36am, Saturday, 14'th Mar 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
01:06pm, Friday, 13'th Mar 2026
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
06:14pm, Wednesday, 11'th Mar 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medici
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade)
06:53am, Wednesday, 11'th Mar 2026
United Therapeutics is upgraded to 'Buy', as ralinepag's Phase 3 success de-risks the pipeline and positions UTHR for further upside. Ralinepag's blockbuster potential, TYVASO's IPF expansion, and a s
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
07:10am, Tuesday, 10'th Mar 2026
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
